Home / Stock ratings / BDX
Stock rating · Surgical & Medical Instruments & Apparatus
Becton, Dickinson and Co. (BDX) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Becton, Dickinson and Co. 66 out of 100 (Favorable). Its highest factor score is catalyst setup at 89, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-06BDX · composite score
About Becton, Dickinson and Co.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) is the legacy medical surgical unit selling catheters, syringes, and infection prevention products. Connected care (24%) includes the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) makes prefillable syringes and autoinjectors. Interventional (29%) covers surgery, peripheral vascular, and urology. More than 60% of revenue comes from the US.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why BDX scores 66/100
BDX's 8 factor scores run from 50 to 89, and 3 of them sit above its composite of 66. Here is how BDX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 13.5x, earnings growth accelerating
- PEG ratio 1.11 (< 1 = undervalued)
- FCF yield 9.1%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 46%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 30 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 30 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BDX compares
As of October 6, 2026, Becton, Dickinson and Co. is tied for 3rd of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 66.
Key risks for BDX
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Becton, Dickinson and Co. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds BDX's momentum and catalyst factors above.
BDX trade plan (Pro)
MELANY has a full position plan for Becton, Dickinson and Co.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BDX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Becton, Dickinson and Co.'s 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BDX
Is Becton, Dickinson and Co. (BDX) a buy?
As of 2026-10-06, MELANY rated Becton, Dickinson and Co. Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Becton, Dickinson and Co.'s MELANY score?
Becton, Dickinson and Co. (BDX) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BDX stock rating calculated?
MELANY scores BDX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Becton, Dickinson and Co. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Becton, Dickinson and Co. (BDX) Favorable with a composite of 66/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BDX stock price forecast?
MELANY does not publish price targets or forecasts for BDX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for Becton, Dickinson and Co., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BDX stock overvalued or undervalued?
MELANY's valuation factor currently reads 68/100 for Becton, Dickinson and Co., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BDX's read.
What price should I buy BDX at?
Rather than chasing the current price, MELANY computes a smart entry zone for BDX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BDX stock?
The top risks MELANY currently flags for Becton, Dickinson and Co.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Becton, Dickinson and Co. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 51/100 for Becton, Dickinson and Co., and earnings track record, at 70/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BDX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 65/100 for BDX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BDX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BDX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BDX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.